NOG

Chr 17

noggin

Also known as: SYM1, SYNS1, SYNS1A

The secreted polypeptide, encoded by this gene, binds and inactivates members of the transforming growth factor-beta (TGF-beta) superfamily signaling proteins, such as bone morphogenetic protein-4 (BMP4). By diffusing through extracellular matrices more efficiently than members of the TGF-beta superfamily, this protein may have a principal role in creating morphogenic gradients. The protein appears to have pleiotropic effect, both early in development as well as in later stages. It was originally isolated from Xenopus based on its ability to restore normal dorsal-ventral body axis in embryos that had been artificially ventralized by UV treatment. The results of the mouse knockout of the ortholog suggest that it is involved in numerous developmental processes, such as neural tube fusion and joint formation. Recently, several dominant human NOG mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) were identified; both SYM1 and SYNS1 have multiple joint fusion as their principal feature, and map to the same region (17q22) as this gene. All of these mutations altered evolutionarily conserved amino acid residues. The amino acid sequence of this human gene is highly homologous to that of Xenopus, rat and mouse. [provided by RefSeq, Jul 2008]

GeneReviewsResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

UniProtSymphalangism, proximal 1A
UniProtMultiple synostoses syndrome 1
UniProtTarsal-carpal coalition syndrome
UniProtStapes ankylosis with broad thumb and toes

Clinical highlights

Gene-disease validity (ClinGen)
NOG-related symphalangism spectrum disorder · ADDefinitivesufficient evidence for diagnostic panels
Interpreting a novel variant
Loss of function is the curated mechanism (Gene2Phenotype) and the gene is intolerant of it in the population — truncating, frameshift and canonical splice variants carry more prior weight here than missense.Curated gene-level mechanism — a prior for triage, not a per-variant call.
1
Active trials
125
Pubs (1 yr)
P/LP submissions
P/LP missense
0.42
LOEUF
LOF
Mechanism· G2P
📖
GeneReview available — NOG
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Moderate LoF intolerance
LoF Constraint?
0.42LOEUF
pLI 0.890
Z-score 2.48
OE 0.00 (0.000.42)
Moderately constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
1.32Z-score
OE missense 0.68 (0.580.81)
94 obs / 137.5 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.00 (0.000.42)
00.351.4
Missense OE?0.68 (0.580.81)
00.61.4
Synonymous OE?1.09
01.21.6
LoF obs/exp: 0 / 7.2Missense obs/exp: 94 / 137.5Syn Z: -0.56

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

NOG · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.